Beckley Psytech to attend and present at 8th Annual LSX World Congress 2022
Beckley Psytech to attend and present at
8th Annual LSX World Congress 2022
Oxford, United Kingdom – 13 April 2022 - Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 8th Annual LSX World Congress, taking place in London from 10th to 11th May 2022, and will hold a formal presentation in front of investors.
- Tuesday, 10th May 2022, 10.30 am ET / 3.30 pm BST
- Please register for the event here
A link to the presentation will be available on the Company's website from 16th May 2022.
The presentation will introduce Beckley Psytech, its target indications, pipeline of drugs and ongoing clinical trials:
- 5-MeO-DMT intranasal formulation safety and tolerability - Phase 1 dose ranging study, and
- low-dose psilocybin Phase 1b in SUNHA[1]
To request a one-on-one meeting with the Beckley Psytech management team, please contact us at gvanrenterghem@lifesciadvisors.com.
[1] Short-lasting unilateral neuralgiform headache attacks
Editor Details
-
Company:
- PharmiWeb.com
-
Name:
- PW Editor
- Email:
-
Telephone:
- +441344851506
